Publication Validates geneType Prostate Cancer Risk Test

MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the publication of a research paper in “The Prostate” validating the utilisation of geneType Prostate Cancer Risk Assessment Test in the identification of men who are at increased risk of this serious disease.

Highlights:

• geneType Prostate Cancer Risk Assessment Test was able to identify 23% more men at high risk of developing prostate cancer than family history alone.
• The study demonstrated that geneType could enable a more targeted approach to Prostate Specific Antigen (PSA) screening of high-risk men – ultimately providing far greater utility of the PSA screening test.

• The study utilised a prospective cohort of almost 200,000 men from the UK Biobank.
• The publication highlights GTG’s commitment to ongoing scientific development of the geneType suite of risk assessment tests – being the 5th publication in the last 6 months – covering ovarian cancer, cardiovascular disease & type 2 diabetes, breast cancer (2) and prostate cancer.

The paper entitled: Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk was published in the journal “The Prostate” by GTG’s scientific team including Dr Erika Spaeth, Dr Richard Allman, Dr Gillian Dite and Dr Nicholas Murphy.

The study demonstrated that geneType Prostate Cancer Risk Assessment Test offered a significant improvement in risk assessment when compared with age and family history in assessing a man’s risk of developing prostate cancer. According to the study, family history alone had a 23% underestimation of risk. Importantly, geneType was we also able to identify men at very low risk of developing prostate cancer.

It is well accepted that PSA screening has drastically increased early-detection rates and reduced late-stage metastatic cancer diagnoses. However, PSA screening has also resulted in increased detection of indolent (non-aggressive) cancer, with a corresponding increase in over diagnosis and over-treatment. Implementation of geneType Prostate Risk Assessment Test could result in a more targeted and focussed approach to PSA screening therefore potentially reducing the need for unnecessary medical intervention.

Dr Erika Spaeth, GTG’s Director of Clinical & Medical Affairs, and an author on the paper, noted “Risk awareness can inform decision-making between clinicians and their patients enabling them to discuss the risks and benefits of PSA screening and ultimately lead to early diagnosis of Prostate Cancer.”

The test is now commercially available with further information is available from GeneType.com.

Authorised for release by the board of directors of Genetic Technologies Limited.

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com

Forward Looking Statements

This announcement may contain forward-looking statements about the Company’s expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. As forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company’s filings with the Securities and Exchange Commission and in its periodic filings with the ASX in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

CONTACT: Enquiries

Investor Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: adrian.mulcahy@automicgroup.com.au